Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on August 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Bradbury, a director at Castle Biosciences, sold shares of the company's common stock on August 12, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• A total of 6,452 shares were sold at a weighted-average price of $26.647, with individual transaction prices ranging from $26.31 to $27.23.
• Following the transactions, Bradbury directly owns 5,021 shares and indirectly owns shares through BioBrit, LLC (30,102 shares), Daniel Bradbury Irrevocable Descendant's Trust (8,550 shares), Annette Bradbury Irrevocable Descendant's Trust (8,550 shares), and The Bradbury Family Trust (13,291 shares).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for corporate insiders to set up 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates